louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00000352: Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1
Official title: Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Opioid-Related Disorders
Substance-Related Disorders
Keywords: opiate dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: University of Pennsylvania
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if addition of dextromethorphan to a stable dose of methadone in opioid dependent subjects will significantly affect physical and psychological aspects of opioid tolerance.


Eligibility criteria: Please contact site for information.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: PDVAMC Treatment Research Center
name: Charles O'Brien, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07009652: Optimization of Transport and Use of a Mobile ECMO Team in Patients With Sudden Cardiac Arrest in the Moravian-Silesian Region
Official title: Proposal for the Organisation of the Procedure for Extracorporeal Cardiopulmonary Resuscitation of Patients With Sudden Cardiac Arrest in the Pre-hospital Environment of the Moravian-Silesian Region
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cardiac Arrest With Successful Resuscitation
Cardiac Arrest, Cause Unspecified
Keywords: cardiac arrest
extracorporeal membrane oxygenation
out-of-hospital cardiac arrest
extracorporeal cardiopulmonary resuscitation
Lead sponsor: University Hospital Ostrava
Sponsor class: OTHER
Collaborators: name: Emergency Medical Services, Moravian-Silesian Region
First posted: 2025-06-06
Enrollment: 100
Sex: ALL
Minimum age (years): 3
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients indicated for ECPR after out-of-hospital cardiac arrest, for whom transport of the patient to an ECMO centre or deployment of an ECMO team is logistically manage-able.

Brief summary: This study evaluates the feasibility of implementing a mobile extracorporeal membrane oxygenation (ECMO) team and optimizing patient transport logistics.

Detailed description: The aim of the study is to improve neurological outcomes in out-of-hospital cardiac arrest (OHCA) cases in the Moravian-Silesian Region. By analysing regional epidemiological and demographic data, the project aims to identify key factors for reducing the time from collapse to the initiation of ECMO and to support the development of effective protocols for extracorporeal cardiopulmonary resuscitation (ECPR).

Eligibility criteria: Inclusion Criteria:

* out-of-hospital cardiac arrest
* indication for ECPR

Exclusion Criteria:

* death at the scene of the accident
* withdrawal of the informed consent

Primary outcomes:
measure: Neurological outcome after 30 days (CPC score)
timeFrame: 30 days
Secondary outcomes:
measure: Time from collapse to initiation of ECMO
timeFrame: Up to 2 hours
measure: Transport time to the ECMO centre
timeFrame: Up to 2 hours
measure: Arrival time for the mobile ECMO team to the scene
timeFrame: Up to 2 hours
Other outcomes:
Locations:
city: Ostrava
country: Czechia
facility: Emergency Medial Services, Moravian-Silesian Region
state: Moravian-Silesian Region
city: Ostrava
country: Czechia
facility: University Hospital Ostrava
state: Moravian-Silesian Region
Study officials:
affiliation: University Hospital Ostravs
name: Nela Walachová, Mgr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03159559: PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes
Official title: A Randomized, Open-label Single-center Trial of Lipo-prostaglandin E1 Improves Coronary Microcirculation Dysfunction in Patients With Ischemic Heart Disease Combine With Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Coronary Microvascular Perfusion in Patients With Ischemic Heart Disease
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2017-05-18
Enrollment: 60
Sex: ALL
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is undertaken to determine if intravenous Lipo-PGE1 therapy would improve coronary microvascular perfusion in patients with ischemic heart disease by CMRI.


Eligibility criteria: Inclusion Criteria:

1. Patients giving written consent after being provided with sufficient explanation about participation in this clinical trial
2. Patients aged between 35-70, no limitation on gender
3. Patients with significant CAD and no need to PCI: 50%-70% luminal stenosis as determined by diagnostic coronary angiography, and left main coronary artery stenosis less than 50%; no history of revascularization procedures before
4. MPRI\<2.0
5. Type 2 DM patients with glycosylated hemoglobin levels\>7%
6. All patients were PGE1-naive, defined as receiving no PGE1 therapy for more than 7 days during the previous 12 months
7. Hypertension remained stable for last 3 months, patients with controlled BP level: SBP\<160mmHg and DBP\<95mmHg

Exclusion Criteria:

1. Patients with a history of allergic to PGE1 or a history of prior PGE1 treatment.
2. History of revascularization procedures before: PCI or CABG
3. Patients with implanted pacemaker or ICD, ventricular assist device and intra-aortic balloon counter pulsation pump
4. Patients who have experienced myocardial infarction
5. Patients with serious systolic left ventricular function failure: echocardiography EF\<25%
6. Claustrophobia
7. Patients who used Insulin pumps
8. SBP\<90mmHg
9. Chronic renal function failure: creatinine level \>2.5mg/dl or 221umol/l
10. Patients with serious or frequent arrhythmia ,atrial fibrillation、frequent ventricular premature contraction、sick sinus syndrome, second- or third degree atrioventricular block
11. Prior non-cardiac illness with estimated life expectancy \<2-yrs
12. Women who are pregnant, lactation,or maybe pregnant in the study period
13. Unable to give informed consent

Primary outcomes:
measure: myocardial perfusion reserve index (MPRI)
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00651859: Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Glaucoma
Ocular Hypertension
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2008-04-03
Enrollment: 111
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the safety and efficacy of once-daily bimatoprost 0.03% and 0.01% ophthalmic solutions compared with once-daily administered bimatoprost vehicle ophthalmic solution for 2 weeks in ethnically Japanese patients with open-angle glaucoma or ocular hypertension


Eligibility criteria: Inclusion Criteria:

* Ethnically Japanese patients with glaucoma or ocular hypertension in each eye who require IOP-lowering therapy in both eyes

Exclusion Criteria:

* Uncontrolled systemic disease
* Use of bimatoprost or an ocular prostaglandin (eg, latanoprost, travoprost) within 6 weeks prior to baseline (Day 0)

Primary outcomes:
measure: Intraocular pressure (IOP)
timeFrame: Day 14
Secondary outcomes:
measure: IOP
timeFrame: Days 2 and 7
Other outcomes:
Locations:
city: San Francisco
country: United States
state: California
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT04908059: Leukemic Phase of ALCL
Official title: Leukemic Phase of ALK+ Anaplastic Lymphoma in Real-life Practice: Experience of a University Clinical Hematology Laboratory
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Anaplastic Lymphoma
Keywords: Anaplastic lymphoma
Leukemic phase
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2021-06-01
Enrollment: 2
Sex: ALL
Minimum age (years): 9
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients presenting a leukemic phase of anaplastic lymphoma

Brief summary: Collecting data about the rare leukemic presentation of anaplastic lymphoma to study the characteristics of patients with leukemic phase of ALCL


Eligibility criteria: Inclusion Criteria:

* Patients presenting a leukemic phase of anaplastic lymphoma

Exclusion Criteria:

* None

Primary outcomes:
measure: A retrospective study of the diagnostic description of the leukemic phases of anaplastic lymphoma in real life
timeFrame: Files analysed retrospectively from January 01, 2020 to December 31, 2020 will be examined]
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Hematology Laboratory - Strasbourg University Hospitals
Study officials:
affiliation: Hematology Laboratory - Strasbourg University Hospitals
name: Laurent MAUVIEUX, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01635959: Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt
Official title: Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Patients With Upper Gastro-intestinal Symptoms
Keywords: upper gastro-intestinal symptoms, GERD
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2012-07-10
Enrollment: 3170
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community patients

Brief summary: The purpose of this study is to calculate the prevalence of gastroesophageal reflux disease (GERD) by mean of GERD-Q questionnaire in patients with upper gastrointestinal tract symptoms in Egypt.

Detailed description: Prevalence of Gastroesophageal reflux disease (GERD) in patients with upper gastrointestinal tract symptoms in Egypt

Eligibility criteria: Inclusion Criteria:

* 18 years and above
* Attending the medical office and reporting symptoms suggestive of upper gastrointestinal tract symptoms such as heartburn/regurgitation, abdominal pain, bloating, belching and nausea/vomiting.

Exclusion Criteria:

* Participating on a clinical trial during the last 3 months.
* Patients not able to read and/or understand the GERD-Q questionnaire.
* Patients already included in the study in other participating site.
* Patients taking PPIs or H2blockers in the l

Primary outcomes:
measure: Percentage of patients scoring ≥ 8 in GERD-Q
timeFrame: baseline
Secondary outcomes:
measure: Socio-demographic characteristics of patients diagnosed with gastroesophageal reflux disease (GERD)
timeFrame: baseline
measure: Treatment patterns in patients diagnosed with gastroesophageal reflux disease (GERD)
timeFrame: baseline
Other outcomes:
Locations:
city: Al MENIA
country: Egypt
facility: Research Site
city: Alex
country: Egypt
facility: Research Site
city: Asuit
country: Egypt
facility: Research Site
city: Aswan
country: Egypt
facility: Research Site
city: Banha
country: Egypt
facility: Research Site
city: Cairo
country: Egypt
facility: Research Site
city: Domiaat
country: Egypt
facility: Research Site
city: Hurghada
country: Egypt
facility: Research Site
city: Ismailia
country: Egypt
facility: Research Site
city: Kafr el-Sheikh
country: Egypt
facility: Research Site
city: Kalubia
country: Egypt
facility: Research Site
city: Luxor
country: Egypt
facility: Research Site
city: Mahala
country: Egypt
facility: Research Site
city: Mansoura
country: Egypt
facility: Research Site
city: Menofia
country: Egypt
facility: Research Site
city: Port-Saeed
country: Egypt
facility: Research Site
city: Qena
country: Egypt
facility: Research Site
city: Sharkiah
country: Egypt
facility: Research Site
city: Sohag
country: Egypt
facility: Research Site
city: Suiz
country: Egypt
facility: Research Site
city: Tanta
country: Egypt
facility: Research Site
Study officials:
name: Dina A Ahmed, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01204359: The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions
Official title: "5010 Clinical Research Programme"of Sun Yat-sen University
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Hypothyroidism
Exophthalmos
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2010-09-17
Enrollment: 627
Sex: ALL
Minimum age (years): 8
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Iodine 131 (131I） treatment on Graves disease and Graves ophthalmopathy relationship has always been the focus of debate. Majority view is that the current treatment does not increase 131I Graves ophthalmopathy, therefore,Graves disease associated with exophthalmos is not a contraindication of 131I treatment. While treatment with corticosteroids, a timely corrective measures to be effective in preventing Graves ophthalmopathy adverse effects. But the merger with severe proptosis in patients with Graves , especially infiltrative exophthalmos , the application of 131I treatment will induce or aggravate not yet reached consensus, so, the 131I treatment is still very careful , mainly due to plaque prospective study and visual assessment is not lack of uniform standards, and a variety of factors (including smoking, work status, and 131I treatment of thyroid doses, etc.) may also interfere or influence the ultimate effect of 131I on the Graves ophthalmopathy. In the view of this situation Graves disease patients with Graves ophthalmopathy could be 131I treatment or not, how to dose adjustments, and the use of which required treatment with systemic issues such as research, explore treatment exophthalmos reduction and mitigation of increased proptosis reasonable treatment of symptoms. To further promote the standardization of 131I treatment of Graves disease on basis.

Detailed description: no more description

Eligibility criteria: Inclusion Criteria:

* a typical clinical symptoms of Graves disease, diffuse goiter, eye signs (including exophthalmos), thyroid function (FT3, FT4, rTSH) and thyroid autoantibodies and imaging examinations to confirmed.

Exclusion Criteria:

* 131I treatment contraindications, those who have not signed the informed consent, failure to complete treatment and follow-up estimates of patients and patients not suitable for radionuclide therapy

Primary outcomes:
measure: The rate of Hypothyroidism after Iodine 131 treatment
timeFrame: one year
Secondary outcomes:
measure: The side effect to Infiltrative exophthalmos after Iodine 131 treatment
timeFrame: one year
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen Memorial Hospital
state: Guangdong
city: Guangzhou
country: China
facility: Ningyi Jiang
Study officials:
affiliation: Sun Yat-sen University
name: SUN YAT-SEN UNIVERSITY ningyi jiang, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03409159: Austrian Left Atrial Appendage Closure Registry
Official title: Austrian Left Atrial Appendage Closure Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Atrial Fibrillation
Left Atrial Appendage Closure
Lead sponsor: Medical University of Graz
Sponsor class: OTHER
First posted: 2018-01-24
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with atrial fibrillation, who received LAAC in Austria.

Brief summary: Left atrial appendage (LAA) occlusion (LAAC) has been introduced to treat patients with indication of oral anticoagulation (OAC) for atrial fibrillation (AF) with contraindication to OAC. This registry aims to document all LAAC procedures in Austria.


Eligibility criteria: Inclusion Criteria:

* Patients who received LAAC in Austria

Exclusion Criteria:

* Absence of informed consent

Primary outcomes:
measure: Number of participants with successful left atrial appendage closure, as defined by European Society of Cardiology Guidelines
timeFrame: 30 days
Secondary outcomes:
measure: Number of participants with death, stroke or bleeding
timeFrame: 5 years
measure: Number of participants with procedure-related adverse events
timeFrame: 30 days
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Medical University of Graz
Study officials:
References:
Clinical trial NCT02158559: the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.
Official title: A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI(ST- Elevation Myocardical Infarction) After the PTCA Surgery.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Myocardial Infarction
Lead sponsor: Beijing Bozhiyin T&S Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2014-06-09
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study focused on the effect of Danhong injection on microcirculation in the treatment of patients with STEMI(ST-elevation myocardical infarction) after the PTCA surgery.

Detailed description: Research Topic.

* A randomized, double-blind, placebo-controlled, multi-center clinical trial of the effect of Danhong Injection on microcirculation in the treatment of patients with STEMI(ST- elevation myocardical infarction) after the PTCA surgery.

Research Purpose.

* This study focused on the effect of Danhong injection on microcirculation in the treatment of patients with STEMI(ST-elevation myocardical infarction) after the PTCA surgery.

Research design.

* A randomized, double-blind, placebo-controlled, multi-center clinical trial.

Eligibility criteria: Inclusion Criteria:

* Clinically definite or laboratory-supported diagnosis of STEMI ,with the indication of PTCA surgery.
* 18≤Age≤75;
* Agreed to join in the study and signed the inform consent form.

Exclusion Criteria:

* Cardiogenic shock , Killip III-IV degree , papillary muscle rupture , septal perforation , episodes of ventricular tachycardia and ventricular fibrillation after electrical cardioversion , temporary pacemaker implanted AVB III degree.
* Past history of PCI and CABG
* Acute or chronic infectious diseases(for example severe pneumonia);
* Recent history of hemorrhagic stroke(within six months)
* Combined with liver and kidney dysfunction;
* History of valvular heart disease;
* Congenital heart disease or Pulmonary hypertension;
* All kinds of history of cardiomyopathy;
* Bleeding and other thrombotic diseases;
* Severe anemia , thrombocytopenia , Other diseases of the blood system;
* Cancer , Autoimmune disease , All kinds of the patients who use the glucocorticoid and immunosuppressor;
* Menstrual period women, pregnant women and lactating women, pregnancy test positive or recent family planning.

Primary outcomes:
measure: After 7 days surgery used magnetic resonance assessed myocardial perfusion and myocardial function.
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06248359: Association Between Postoperative Administration of L-Arginine and CSA-AKI
Official title: Association Between Early Postoperative L-Arginine Administration and Acute Kidney Injury Following Cardiac Surgery
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Acute Kidney Injury
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2024-02-08
Enrollment: 7000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who were admitted to the ICU after cardiac surgery with CPB.

Brief summary: To investigate the association between the the early administration of L-Arginine after CPB-assisted cardiac surgery and the incidence of CS-AKI in adult patients. To test if it can reduce the incidence of post-operative AKI.


Eligibility criteria: Inclusion Criteria:

* adult patients (over 18 years)
* underwent CPB assisted cardiac surgery
* admitted to ICU

Exclusion Criteria:

* congenital heart disease
* underwent deep hypothermic circulatory arrest (DHCA)
* with glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²

Primary outcomes:
measure: incidence of postoperative AKI
timeFrame: from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 30 days
Secondary outcomes:
measure: Renal failure
timeFrame: from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 30 days
measure: in-hospital mortality
timeFrame: from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 30 days
measure: length of in-hospital stay
timeFrame: from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 30 days
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital
state: Shaanxi
Study officials:
affiliation: Xijing Hospital
name: Chong Lei
role: PRINCIPAL_INVESTIGATOR
References: